Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma

Lisa D. Erickson, Lynn C. Hartmann, John Q. Su, Skott N.J. Nielsen, Delano M. Pfeifel, Richard M. Goldberg, Ralph Levitt, C. Robert Stanhope

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

A phase II study of cyclophosphamide, cisplatin, and leuprolide acetate after debulking of stage III or IV ovarian carcinoma was conducted in 33 patients through a cooperative group study involving 11 institutions. The intent was to determine whether the addition of a gonadotropin-releasing hormone analogue would alter the response rates and toxicity profile of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Twenty-nine patients completed all 6 planned cycles. Of the 19 patients who had second-look laparotomy, 12 had persistent disease and 7 were negative for disease. The use of a gonadotropin-releasing hormone with combined chemotherapy did not alter the toxicity profile or the effectiveness of chemotherapy when comparisons were made with historical controls.

Original languageEnglish (US)
Pages (from-to)196-200
Number of pages5
JournalGynecologic oncology
Volume54
Issue number2
DOIs
StatePublished - Aug 1994

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma'. Together they form a unique fingerprint.

Cite this